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http://www.biomedcentral.com/1471-2296/15/157RESEARCH ARTICLE Open AccessFunctional and self-rated health mediate the
association between physical indicators of
diabetes and depressive symptoms
Sylvia Boehme1*, Christian Geiser2 and Babette Renneberg1Abstract
Background: Depression is common among persons with diabetes and associated with adverse health outcomes.
To date, little is known about the causal mechanisms that lead to depression in diabetes. The aim of the present
study was to examine to which extent functional and self-rated health mediate the association between physical
health and depressive symptoms in diabetes.
Methods: Data of n = 3222 individuals with type 2 diabetes were analyzed cross-sectionally and longitudinally at
three measurement occasions using path analysis. Indicators of physical health were glycemic control, number of
comorbid somatic diseases, BMI, and insulin dependence. Furthermore, functional health, self-rated health and
depressive symptoms were assessed.
Results: The effects of physical health on depressive symptoms were largely mediated by functional health and
self-rated health. There was only a weak indirect effect of physical health on depressive symptoms. In contrast,
self-rated health was a strong direct predictor of depressive symptoms. Self-rated health in turn depended
strongly on patients’ functional health.
Conclusions: The way individuals perceive their health appears to have a stronger effect on their depressive
symptoms than objective physical indicators of diabetes. Therefore practitioners should be trained to pay
more attention to their patients’ subjective health perceptions.
Keywords: Chronic diseases, Depression, Diabetes, Health care, Self-rated healthBackground
Depressive symptoms are highly prevalent in patients
with diabetes [1]. Anderson et al. [1] reported a preva-
lence rate of depression twice as high in patients with
diabetes than in a comparison group without diabetes.
Patients with comorbid depressive symptoms have
higher mortality rates [2], more diabetes-related com-
plications [3], a decreased quality of life, [4] as well
as a higher symptom burden [5]. Furthermore, de-
pression especially in physical illness is challenging as
people’s beliefs about depression may compromise de-
pression screening and therapy [6]. Therefore, appropri-
ately identifying and treating depressive symptoms in* Correspondence: sylvia.boehme@fu-berlin.de
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neglected issue.
Although the high prevalence of depressive symptoms
in patients with diabetes is well established, empirical
evidence on a potential relationship between physical
indicators of diabetes and psychological variables is in-
consistent. While some studies found significant associa-
tions between depression and glycemic control e.g. [7,8]
others found no such relationship [9]. In a recent review,
effects of antidepressive therapy on glycemic control in
patients with diabetes and depression were contradictory
[10]. Furthermore, the causal direction of the relation-
ship between physical symptoms of diabetes and depres-
sive symptoms remains unclear. A large meta-analysis
found that depression may constitute a risk factor for
diabetes [11] but there is also strong meta-analytic evi-
dence for depression being a consequence of diabetes [12].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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the mechanisms underlying the relationship between de-
pression and diabetes. Specifically, this study examines
the relationship between physical indicators of diabetes,
functional health (FH), self-rated health (SRH), and their
effects on depressive symptoms In the present study, we
adapted the theoretical model proposed by Whitelaw
and Liang [13], in which PH, FH, and SRH are causally
linked and FH serves as a mediator between chronic ill-
ness and SRH (see Figure 1). Compared to SRH, FH
reflects a specific aspect of health-related quality of life
(HRQoL). FH is defined as the ability of an individual to
perform and adapt to his or her environment. We ex-
tended Whitelaw and Liang’s model by including mental
health (i.e., depression) as the final outcome variable of
PH, FH, and SRH. In addition to including depressive
symptoms as a mental health outcome, we examined
multiple disease-specific measures of PH as well as dif-
ferent indicators of FH. In the present article, we present
analyses of cross-sectional as well as longitudinal data.
Strong associations have been reported for the rela-
tionship between SRH and depression among people
with diabetes. SRH refers to an individual’s perception of
his or her current health and has been shown to be a
strong predictor of morbidity, hospitalization, and mor-
tality in the elderly [14,15]. In addition, a recent review
found strong negative associations between health-
related quality of life HRQoL; [16] and depression in
people with diabetes [17].
Ali et al. [17] proposed that SRH should be examined
as a mediator between diabetes and depressive symp-
toms in order to improve understanding of the mecha-
nisms that lead to depression in diabetes. To the best of
our knowledge, there has only been one study so far that
has addressed this issue. Jang et al. [18] confirmed that
SRH mediates the relationship between diabetes and de-
pressive symptoms. In this study, however, the level of
diabetes severity was not assessed.
Our study aimed at investigating the mechanisms of
depression in diabetes within a framework of physicalFigure 1 Extended path model based on Whitelaw and Liang’s theore
outcome of PH, FH, and SRH in type 2 diabetes.and functional health predicting SRH and depressive
symptoms. We expected to see a higher prevalence of
depressive symptoms in persons with diabetes compared
to the general population. Furthermore, using the path
model in Figure 1, we tested whether PH was directly
associated with depressive symptoms above and beyond
FH and SRH. Moreover, we tested the hypothesis that
FH and SRH serve as mediators of the relationship be-
tween PH and depressive symptoms in diabetes.
Methods
Participants and Procedure
Data from randomly selected insurants of a German
health insurance company (Techniker Krankenkasse)
meeting criteria for type 2 diabetes (according to their
physician’s diagnosis) were used for the present analyses.
The study was conducted according to the ethical guide-
lines of the insurance company. Authors obtained permis-
sion from the health insurance to analyze the de-identified
data. Further ethics approval was not required as per
German ethical guidelines. The questionnaires were sent
by mail to the participants by the insurance company. Indi-
viduals who did not suffer from dementia or severe mental
diseases, provided written informed consent, and returned
at least the first of three questionnaires were included in
the study. Measurements were taken at recruitment as well
as four and ten months after recruitment, respectively. The
following analyses are based on a subsample of 3,222 par-
ticipants (male n = 2541, female n = 681, mean age = 68.11,
SD = 7.70). Participants and non-participants (individuals
who did not return the first questionnaire) did not differ in
gender or number of diagnoses (p < .001) but participants
were significantly younger than non-participants (67.08 vs.
69.70 years; p < 0.05). Comprehensive sample characteris-
tics are presented in Table 1. A participants’ flow diagram
is presented in Figure 2.
A subset of 2,458 persons out of a total of 3,222 par-
ticipants reported their blood glucose level (HbA1c) at
first assessment. To test whether participants with and
without available HbA1c differed with regard to their meantical model with depressive symptoms as final mental health
Table 1 Sample characteristics
T1 T2 T3
valid n n (%) valid n n (%) valid n n (%)
N 3222 1823 1867
Gender 3222 1823 1867
Female 681 (21.1) 380 (20.8) 382 (20.5)
Male 2541 (78.9) 1443 (79.2) 1485 (79.5)
Insulin Dependent 3222 1467 (45.0) 1823 869 (47.7%) 1867 924 (49.5)
Critical Blood
Glucose Level 2458 1065 (32.6) 258 155 (60.1) 239 126 (52.7)
(HbA1c >7.0%)
Depressive Symptoms WHO-5a 2876 1633 1665
<28 (indicates MDD) 546 (16.9) 269 (16.5) 320 (19.2)
<52 (poor emotional well-being) 591 (18.3) 327 (20.0) 314 (18.9)
M (SD) M (SD) M (SD)
Age (years) 3140 68.11 (7.70) 1785 68.55 (7.48) 1826 68.47 (7.5)
Gender (women = 0, men = 1) 3222 .79 (.41) 1823 .79 (.41) 1867 .80 (.40)
BMI 3088 30.05 (5.38) 1768 30.18 (5.75) 1812 30.1 (5.5)
Blood Glucose Level in% (NGSP) 2458 6.92 (.89) 258 6.92 (.95) 239 6.87 (.84)
No. of diagnoses 3222 4.63 (1.53) / /
SRHb 2924 5.3 (1.95) 1627 5.49 (2.0) 1661 5.46 (1.96)
FH (Total Score)c 3160 .76 (.25) 1791 .76 (.25) 1528 .76 (.25)
Mobilityd 3202 1.51 (.51) 1814 1.51 (.51) 1549 1.52 (.51)
Self cared 3200 1.13 (.37) 1811 1.13 (.37) 1547 1.14 (.38)
Usual activitiesd 3188 1.43 (.55) 1807 1.43 (.56) 1543 1.43 (.56)
Pain/discomfortd 3196 1.94 (.59) 1812 1.93 (.59) 1546 1.93 (.60)
Anxiety/depressiond 3195 1.38 (.55) 1813 1.37 (.54) 1544 1.34 (.52)
Depressive Symptoms WHO-5 (total score)a 2876 56.72 (24.46) 1633 58.34 (24.30) 1665 57.01 (24.91)
aRange: 1–100; higher scores indicating better emotional well-being.
bRange: 1–10; higher scores indicating better SRH.
cRange: −0.207-1; higher scores indicate less functional impairment.
dFH Subscales Range: 1–3; higher scores indicate higher functional impairment.
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sensitivity analyses. We found significant differences in
means (0.19 ≤ d ≤ 0.34) between those who reported their
HbA1c and those who did not
a. To examine whether these
differences would affect the results of the path analysis, we
ran the analysis separately for the reduced sample of 2,458
persons (using listwise deletion of missing values) and the
full sample of 3,222 persons (using full information max-
imum likelihood [FIML] estimation with missing data).
Differences in results between the reduced and the full
sample were marginal. Thus, we will report the results for
the full sample with FIML estimation below.
Measures
Physical health measures (PH)
As a measure of glycemic control, participants reported
their blood glucose level (HbA1c) according to their latestlaboratory test results. An HbA1c > 7.0% was regarded as
critical. HbA1c was used as a continuous variable in the
analyses. The number of comorbidities was calculated from
insurance data by summing up all diagnoses from a list of
11 diseases that a participant had been diagnosed with in
the previous 12 months before participation (arthrosis,
cancer, hypertension, coronary heart disease, arterioscler-
osis, myocardial infarction, chronic heart failure, stroke,
COPD, asthma, diabetes). Furthermore, participants re-
ported their insulin-dependence, weight and height.
Self-Rated Health (SRH)
SRH was assessed using a well-established and validated
single item measure e.g., [19]. Participants were asked to
estimate their SRH on a scale ranging from 0 (“very
poor”) to 10 (“very good”). The exact wording was: “If
you were to rate your general state of health on a scale
Figure 2 Participants’ flow diagram according to CONSORT statement.
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meaning “couldn’t be better”), how would you rate your
current state of health?”
Functional Health (FH)
To assess FH, the following subscales of the EQ-5D
were used: mobility, self-care, usual activities, and
pain/discomfort (3-point scale from 1 = ‘no problems’
to 3 = ‘severe problems’). Subscale scores were com-
puted according to the EQ-5D value sets [20]. Larger
scores indicate fewer functional limitations. The sub-
scales mobility, self-care, usual activities, and pain/
discomfort were entered separately into our model. The
subscale anxiety/depression was used as an indicator for
the mental health outcome as described below.
Depressive Symptoms
To assess depressive symptoms, we used the World-
Health-Organization-Five scale (WHO-5), which is a
brief and widely used measure of emotional well-being
e.g., [21]. The WHO-5 has shown excellent internal
consistency (Cronbach’s α = .91) and good external val-
idity against SCID of 80% [22,23]. Also, the comparative
validity against physicians’ diagnoses showed to be
excellent. While physician sensitivity for detecting majordepressive disorder was only 40%, WHO-5 Screening iden-
tified 94% of patients with major depressive disorder [22].
According to the WHO a score < 52 indicates poor emo-
tional well-being, and a score < 28 is regarded as an indica-
tor of a major depressive disorder [22,23]. Higher scores
indicate fewer depressive symptoms. As a second indicator
of depressive symptoms, we used the anxiety/depression
subscale of the EQ-5D. According to the proposed model,
depressive symptoms are regarded as the distal outcome.
Therefore, the anxiety/depression subscale of the EQ-5D
was used as an outcome variable instead of a predictor
variable in terms of functional health.
Statistical Analyses
The cross-sectional associations of PH, SRH, and FH
with depressive symptoms in diabetes were examined by
estimating the path coefficients of the proposed path
analytic model using time 1 data only (see Figure 1). In
the path model, the HbA1c value, insulin-dependence,
the number of diagnoses, and the BMI were used as sep-
arate indicators of PH. The EQ-5D subscales (except
anxiety/depression) were used as separate indicators of
FH. SRH was represented in the model by the single
item measure. Finally, we included both the total WHO-5
score and the anxiety/depression subscale of the EQ-5D as
Table 2 Pearson correlations of health constructs and
physical indicators of diabetes with measures of











Usual Activities -.52** .35**
Pain/Discomfort -.43** .31**
BMI -.17** .10**
Blood Glucose Level -.09** .03
in mmol/mol (IFCC)
in% (NGSP)





Note. aHigher scores indicate a smaller level of depressive symptoms; **p < .01.
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and gender were included as covariates in the model.
Dummy variables were created for gender (0 = women,
1 = men) and insulin-dependence (0 = not insulin-
dependent, 1 = insulin-dependent). Our model was a
“full forward model” [24], in which all direct paths
from each construct to all other constructs following
them in the proposed causal order shown in Figure 1
were estimated. The model also included all possible
correlations between the exogenous physical symptoms
variables and covariates as well as correlated residual var-
iables for all endogenous variables at the same level in
the model and thus represented a saturated model. To
confirm the results found in the cross-sectional approach
we ran additional longitudinal path analyses using a
cross-lagged panel design [25] in which each variable was
regressed on both its own previous measure(s) and the
lagged measures of the other variables at previous meas-
urement occasions. Longitudinal cross-lagged analyses
allow for stronger tests of the proposed causal ordering
of the variables. In our path analyses, we used FIML esti-
mation to take all available data point into account [26].
In the cross-lagged panel model, the T1-measures of PH,
the FH-subscales, SRH and the two measures of depres-
sive symptoms as well as the covariates age and gender
were included as separate indicators of following T2
and T3 measures: BMI, insulin dependence, the FH
subscales, SRH, WHO-5 score and the anxiety/depression
subscale of the EQ-5D. Due to the great amount of missing
data for HbA1c at later assessments the T2 and T3 mea-
sures of HbA1c could not be included in the longitudinal
analyses.
Ethical approval
The data collection was conducted and ethically approved
by the German health insurance company Techniker
Krankenkasse. The current participants did not participate
in any intervention over the course of the data collection.
Results
A total of N = 3222 participants with diabetes were in-
cluded in the study. Sample characteristics with means
and standard deviations for all variables and assessment
points are displayd in Table 1.
Depressive Symptoms
Participants with type 2 diabetes showed a mean WHO-
5-Score of 56.72 (SD = 24.46). According to WHO-5
definitions [22,23], 16.9% of the sample showed severe
depressive symptoms (WHO-5 scores < 28) and an add-
itional 18.3% of the participants showed poor emotional
well-being (WHO-5 scores < 52).
The zero-order correlations between the SH, FH, and
PH measures and the two depression outcome variablesat the first measurement occasion are presented in
Table 2. Both measures of depression were substantially
and significantly related to all measures of SH and FH.
There were fewer and weaker correlations among the
depression measures and measures of PH. The largest
absolute correlation between PH and depression was
found between the number of diagnoses and the WHO
depression score (r = −.272, p < .001). The HbA1c score
was only marginally correlated with the WHO depres-
sion score (r = .088, p < .001) and not at all correlated
with the EQ-5D anxiety/depression subscale (r = .025, n.s.).
Slightly higher and statistically significant correlations were
found between the BMI and these measures.
Cross-sectional path analyses
Table 3 displays the results of the path analysis in terms
of the estimated path coefficients and R2 values for
each endogenous variable in the model. As displayed in
Figures 3a and 3b, the number of diagnoses showed
strong standardized path coefficients for predicting each
of the four FH outcomes (β > 0.10). In addition, the
BMI and insulin-dependence variables had significant
effects on all four indicators of FH, whereas the blood
glucose level (in terms of the HbA1c value) did not
have a significant effect on any of the FH outcomes. In
total, between 4 and 11% of the variability in FH mea-
sures were explained by PH indicators in the model.
Furthermore, Figure 3b shows that indicators of FH
were the strongest predictors of SRH with all four
standardized path coefficients related to indicators of
Table 3 Estimated path coefficients, standard errors, significance tests, and measures of fit for the proposed path model
Paths B SE(B) β p R2 SEE
Mobility on .11 0.48
Number of diagnoses 0.07 0.01 0.20 < .001
BMI 0.02 0.01 0.21 < .001
Insulin-dependence 0.11 0.02 0.11 < .001
Blood glucose level −0.01 0.01 −0.01 .68
Gender −0.07 0.02 −0.06 < .001
Age 0.00 0.00 0.06 .001
Self-care on .04 0.36
Number of diagnoses 0.02 0.02 0.10 < .001
BMI 0.01 0.01 0.12 < .001
Insulin-dependence 0.07 0.01 0.09 < .001
Blood glucose level −0.02 0.01 −0.04 .09
Gender −0.01 0.02 −0.01 .54
Age 0.00 0.00 0.07 < .001
Usual activities on .09 0.53
Number of diagnoses 0.08 0.01 0.21 < .001
BMI 0.02 0.00 0.15 < .001
Insulin-dependence 0.11 0.02 0.10 < .001
Blood glucose level 0.00 0.01 0.01 .82
Gender −0.13 0.02 −0.10 < .001
Age −0.00 0.00 −0.03 .07
Pain/discomfort on .09 0.57
Number of diagnoses 0.07 0.01 0.19 < .001
BMI 0.02 0.00 0.17 < .001
Insulin-dependence 0.12 0.02 0.10 < .001
Blood glucose level −0.01 0.01 −0.01 .56
Gender −0.18 0.03 −0.12 < .001
Age −0.00 0.00 −0.05 .01
SRH on .39 1.53
Mobility −0.69 0.07 −0.18 < .001
Self-care −0.53 0.09 −0.10 < .001
Usual activities −0.78 0.07 −0.22 < .001
Pain/discomfort −0.80 0.06 −0.24 < .001
Number of diagnoses −0.12 0.02 −0.10 < .001
BMI −0.01 0.01 −0.03 .07
Insulin-dependence −0.14 0.06 −0.04 .02
Blood glucose level −0.10 0.04 −0.05 .007
Gender −0.07 0.07 −0.01 .34
Age 0.03 0.00 0.10 < .001
Depressive Symptoms (WHO-5)(WHO-5) on .43 18.51
SRH 4.53 0.24 0.36 < .001
Mobility −0.64 0.87 −0.01 .46
Self-care −5.04 1.10 −0.08 < .001
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Table 3 Estimated path coefficients, standard errors, significance tests, and measures of fit for the proposed path model
(Continued)
Usual activities −10.48 0.84 −0.24 < .001
Pain/discomfort −4.67 0.72 −0.11 < .001
Number of diagnoses −0.33 0.25 −0.02 .18
BMI 0.05 0.07 0.01 .44
Insulin-dependence 1.17 0.75 0.02 .12
Blood glucose level −0.74 0.48 −0.03 .12
Gender 2.64 0.87 0.04 .002
Age 0.35 0.05 0.11 < .001
Anxiety/depression on .22 0.49
SRH −0.06 0.01 −0.20 < .001
Mobility −0.05 0.02 −0.04 .04
Self-care 0.12 0.03 0.08 < .001
Usual activities 0.17 0.02 0.18 < .001
Pain/discomfort 0.12 0.02 0.13 < .001
Number of diagnoses 0.00 0.01 0.00 .97
BMI −0.00 0.00 −0.02 .36
Insulin-dependence −0.06 0.02 −0.06 .001
Blood glucose level −0.00 0.01 −0.00 .84
Gender −0.13 0.02 −0.09 < .001
Age −0.01 0.00 −0.16 < .001
Note. N = 3222. B = unstandardized path coefficient. SE = standard error; β = standardized path coefficient; SEE = standard error of estimate (estimated standard
deviation of the residual variable).
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gender differences in SRH once the other variables were
controlled for in the analysis. Overall, the model accounted
for 39% of the variability in SRH.
For the two final outcome measures of depressive
symptoms, SRH was the strongest predictor of depres-
sive symptoms (β > |0.20|; p < .001). Furthermore, the
usual activities subscale used as an indicator of FH
showed a relatively strong direct incremental effect on both
indicators of depressive symptoms (β > |0.18|; p < .001).
Figure 3c shows the results on depressive symptoms in
terms of the WHO-Five measure.
In terms of the measures of PH, the path coefficients
for number of comorbid diagnoses, BMI, and the HbA1c
score were consistently non-significant for both outcome
measures supporting the mediating effect of FH and
SRH in the association of PH and depressive symptoms.
Insulin dependence had significant direct effects on the
anxiety/depression subscale (β > |0.06|; p < .001) but not
on depressive symptoms assessed via the WHO-Five.
Overall, 43% of the variability in the WHO-5 scores
and 22% of the variability in the anxiety/depression
subscale scores of the EQ-5D were explained in the
model. A separate analysis in which only the measures
of PH were used as predictors of the depression scoresrevealed that the PH measures alone accounted for only
5.2% of the variability in the WHO-5 scores and only
1.3% of the variability in the EQ-5D anxiety/depression
scores.
Indirect effects
Table 4 shows the 95% confidence intervals for the indir-
ect effects which were estimated based on bias-corrected
bootstrapping [27]. The indicators of PH and FH were
significantly indirectly related to SRH and depressive
symptoms. Only blood glucose level did not show any
significant indirect relation to either one of the outcome
measures.
Longitudinal path analyses
To reduce complexity we only report significant and dir-
ect associations (beyond the autoregressions). For fur-
ther details on the longitudinal results see Additional
file 1: Table S1. The PH indicators number of comorbid
diagnoses, insulin-dependence, and BMI predicted FH at
T2. Blood glucose level did not predict FH longitudin-
ally. At T3 of all previous PH variables only the number
of diagnoses predicted two FH subscales (mobility
and usual activities), and insulin-dependence predicted
mobility. At T2 SRH was predicted by the number of
Figure 3 Path models. a. Path model Part I: FH outcomes. b. Path model Part II: SRH outcome. c. Path model Part III: Depressive Symptoms in
terms of WHO-Five. Note: non- significant paths are displayed in a dotted line; ***p < .001.
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FH subscales mobility and pain/discomfort. At T3 of all
PH and FH indicators only the number of diagnoses pre-
dicted SRH. Depressive symptoms (WHO-5) at T2 were
predicted by the number of comorbid diagnoses and theTable 4 Indirect effects according to proposed paths in Figur
SRH Depressive sympto
Estimate 95% CI SE Estimate
PH indicators
Number of diagnoses −0.14* (−.16; −.12) .01 −0.17* (−
BMI −0.12* (−.14; −.10) .01 −0.12* (−
Insulin-dependence −0.08* (−.10;-.05) .01 −0.08* (−




Usual activities −0.08* (−
Pain/ discomfort −0.09* (−
Note. Standardized parameter point estimates and bias-corrected bootstrapped
lower and upper boundaries; SE = Standard Error; *p < .001; nsnot significant.FH subscale self-care. At T3 the number of diagnoses
and previous mobility predicted depressive symptoms
(WHO-5). Of all PH, FH, and SRH indicators only the
number of diagnoses predicted the anxiety/depression
scale at T3 but not at T2, where no significant directe 1
ms (WHO Score) Depressive symptoms (anxiety/depression)
95% CI SE Estimate 95% CI SE
.19; −.15) .01 .11 (.09; .13) .01
.15; −.09) .01 .08 (.06; .10) .01
.11; −.06) .01 .06 (.04; .07) .01
−.04; .02) .01 .01 (−.02; .029 .01
.08; −.05) .01 .04 (.03; .05) .01
.05; −.02) .01 .02 (.01; .03) .00
.10; −.06) .01 .05 (.03; .06) .01
.10; −.07) .01 .05 (.04; 06) .01
(10.000 samples) CIs and SEs for indirect effects; CI = Confidence Interval:
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autoregressive effects. Furthermore, SRH was found to be
the strongest predictor of depressive symptoms at T2 (for
WHO-5 score and the anxiety/depression subscale).
Discussion
The aim of our study was to shed more light on the
causes of depression in diabetes. For this purpose, we
considered both patients’ objective PH status and more
subjective health constructs such as FH and SRH and stud-
ied their interplay within a large population using a com-
plex path model adapted from Whitelaw and Liang [13].
Summary of findings
As expected, the participants in our study showed a sig-
nificantly higher level of depressive symptoms compared
to the general population. With a mean score of 57 on a
scale from 0–100 our study’s participants showed con-
siderably more depressive symptoms than the general
population for which Bech et al. [21] reports a mean
score of 69. This is even more remarkable as our sample
consists of a considerable high percentage of male par-
ticipants who usually report less depressive symptoms
than women. First, our results confirm Whitelaw and
Liang’s proposed model [13] regarding the strong rela-
tionship between PH, FH, and SRH in diabetes. Second,
our extension of their model to predicting mental health
as a distal outcome helped us clarify that SRH and FH
predict depressive symptoms in diabetes and that these
constructs to a large extent mediate the effect of PH on
depressive symptoms in diabetes. Altogether, our cross-
sectional model accounted for over 40% of individual
differences in depressive symptoms as measured by the
WHO-5 scale, which can be seen as a large effect. In
contrast, PH measures alone accounted for only between
3.5 and 9.5% of the variability in depression. Moreover,
we were able to confirm Whitelaw and Liang’s model for
diabetes with more differentiated indicators of PH than
those used by Whitelaw and Liang and confirmed the
cross-sectional results also longitudinally. The longitu-
dinal analyses also showed previous SRH to be the
strongest predictor of depressive symptoms at second
assessment (T2) whereas PH had an at most modest
longitudinal association.
Study results concerning the causal mechanisms under-
lying the relationship between diabetes and depression are
contradictory. The purpose of the present study was not
to study causal relations of diabetes and depression but
to examine the factors that may lead to depressive
symptoms in already existing diabetes. But we also run
additional longitudinal analyses that showed that the
binary measure insulin dependence at T3 was signifi-
cantly predicted by baseline anxiety/depression (β = |.38|;
p < .05). We also found a cross-sectional direct significantassociation between insulin-dependence and anxiety/
depression at T1 although there was no such relation-
ship with the WHO-Five score (over and above all
other measures in the model). These results suggest a
relationship between physical and mental health that
needs to be further examined. Also, previous studies
have shown that one of the most important predictors
of anxiety in persons with diabetes is the incidence or
fear of hypoglycemia e.g. [28] which might affect the
anxiety/depression subscale and explain why there is
no such relationship with depressive symptoms in
terms of the WHO-Five score in our data. The fear of
hypoglycemia might be higher in persons who are insu-
lin dependent as the use of insulin is associated with
increased episodes of hypoglycemia [29]. Therefore the
predictive value of the proposed model might increase
and explain more variability in mental health when
anxiety-specific measures like the Hypoglycaemia Fear
Survey [30] are included.
In summary, the results of the current study show that
subjective health constructs (FH, SRH) account for a
considerable amount of the variance in depressive symp-
toms in individuals with diabetes. It appears that the
perception of impairment and health affect emotional
well-being and depressive symptoms more directly than
physical correlated of diabetes. As a consequence, sub-
jective health constructs should receive more attention
from health practitioners in diabetes care. Individuals’
perceptions of their health status rather than objective
indicators of PH are what may be most strongly related
to depressive symptoms in diabetes.
Comparison with existing literature
There is a substantial gap between research findings
regarding the relationship of diabetes and depression
and general practice. It is well-known that depressive
symptoms are not recognized in general practice in
about half the general patients and especially in pa-
tients with diabetes [31]. Even if recognized, most
cases are not treated according to the guidelines for
treatment of depressive disorders [32]. Previous studies
recommend a monitoring of subclinical or minor de-
pression for people with type 2 diabetes [33-35]. We
propose to include preliminary assessments of SRH
into regular diabetes screening, monitoring of the de-
velopment, and, if indicated, address the issue with the
patient or refer him or her to a psychologist for fur-
ther depression screening. e.g. [8,36].
There have been a few approaches to improve treat-
ment of individuals with diabetes and depression. Behav-
ioral approaches to improve patients’ glycemic control
could show that a stress management program can re-
sult in benefits for patients with type 2 diabetes e.g. [37].
Also, for example, Osborn et al. successfully developed
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tients with depression and diabetes [38]. More and further
approaches in education of patients and health practi-
tioners are necessary. According to the current re-
sults, interventions that aim to reduce the perceived
functional impairment could thereby be effective. This
was also the conclusion of a recent meta-analysis that
showed how strongly activity-restriction and depres-
sion were correlated in medical patients [39]. From a
psychological perspective two possible approaches to
address impairment known as structural and behav-
ioral prevention [40] have been discussed. Structural
prevention in this regard could include improving access
to diabetes-specific health support such as medical foot
care or improved food-labels to prevent adverse effects
of inappropriate nutrition. The behavioral approach com-
prises elements of cognitive behavioral therapy such as
cognitive reframing that might aim on emphasizing on as-
pects that are less impaired or reducing the perceived im-
portance of specific functional impairments. In addition,
training of appropriate disease management and self-care
and thereby promoting diabetes literacy might be ef-
fective in reducing depressive symptoms in individuals
with diabetes.
Limitations
The results only apply to clinically diagnosed diabetes
and therefore might not be valid for undiagnosed dia-
betes as we cannot assess how knowing about a certain
diagnosis and probably be treated accordingly might
affect health perception and behavior. Also, we were not
able to control for the duration of diabetes, which might
be an important factor of perceived physical impairment
and SRH and should be included in future studies. The
WHO-5 is a questionnaire that assesses general well-
being and can be used as a screening test for clinical de-
pression [23,41], but it is not a standardized clinical
interview. Therefore our data does not provide a reliable
clinical classification of depressive symptoms. More mea-
sures of mental health should be included in future studies
to clarify the mental health domain.
The number of comorbid diagnoses seems to be a
promising variable to determine disease burden and
overall physical health. Unfortunately we did not have
enough information to calculate, for example, a Charlson
Comorbidity Index, which would be even more mean-
ingful in terms of physical health as it is a strong pre-
dictor of mortality.
Another limitation of our study is the relatively high
drop-out over time in the longitudinal part of the study.
We addressed the problem of missing data by using
FIML estimation, which allowed us to include all avail-
able data points in the analysis. FIML is currently the
state-of-the art in missing data analysis, as it allowsretaining high statistical power in the presence of miss-
ing data [42]. Furthermore, by including auxiliary vari-
ables in the analyses (e.g., the Time-1 variables in the
case of longitudinal analyses), bias is reduced relative to
listwise deletion or other ad hoc missing data handling
strategies. In the case of our longitudinal analyses, the
covariance coverage remained relatively high (most co-
variance coverage values in terms of the proportion of
data present to estimate a given variance or covariance
were in the 60 to 70% range, with only a few values fall-
ing below 50% and no values falling below 40%, indicat-
ing that there was enough information available to
estimate the path coefficients reliably in our longitudinal
model. Nonetheless, it would be desirable to obtain more
complete data in future studies if possible.
The strong associations between FH and SRH indica-
tors and depressive symptoms may in part be explained
by shared method effects, given that almost all these
constructs were based on self-report measures. This may
have led to an overestimation of the amount of ex-
plained variability in depressive symptoms due to shared
method variance. Future studies should attempt to ob-
tain additional objective measures of these constructs to
control for potential effects of shared method variance.
Furthermore, one could argue that the indicators of de-
pressive symptoms and SRH share some conceptual
similarity, and that this may explain the strong associa-
tions between SRH and depression in our study. On the
other hand, Kudielka et al. [43] provided support for the
argument that although depression and SRH are related
concepts, they constitute distinct psychological entities.
In our study, we found strong correlations between de-
pression and measures of SRH, although all correlations
were < .6, indicating a substantial amount of discrimin-
ant validity.
Conclusions
The current results indicate that physical symptoms
have only weak direct effects on depression, whereas the
subjective ratings of health (SRH and FH) are strongly
related to emotional well-being and depressive symp-
toms. Therefore, practitioners should be trained to pay
more attention to the individual and potentially dysfunc-
tional perception of the chronic disease. Our results
contribute to the growing body of research that regards
SRH as an important measure that might help identify-
ing patients who require an early intervention.
Endnote
aIndividuals with available HbA1c scores are significantly
older (p < .05), report a significantly higher SRH (p < .001),
HrQoL (p < .001) and emotional well-being (p < .001) and
are more likely to be insulin dependent (p < .001) than
individuals without available HbA1c (48.7% vs. 33.4%).
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